Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 10/20 | 0.56 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.56 |
| ▸ | JAK2 | O60674 | 4/20 | 0.56 |
| ▸ | JAK1 | P23458 | 2/20 | 0.56 |
| ▸ | TYK2 | P29597 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2480978 | 1.00 | JAK3 (0.56) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL2485490 | 0.91 | NPC1 (0.49) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL2483610 | 0.87 | JAK3 (0.58) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL2483165 | 0.87 | JAK3 (0.54) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL2482209 | 0.82 | JAK3 (0.63) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL2478606 | 0.78 | PTPN2 (0.49) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL2481270 | 0.78 | JAK3 (0.69) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL2477457 | 0.77 | JAK3 (0.55) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL2477458 | 0.77 | JAK3 (0.55) | JAK3IRAK4JAK2JAK1TYK2 | |
| SCHEMBL2476807 | 0.76 | JAK3 (0.66) | JAK3IRAK4JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575153-B2 | Pyridine-3-carboxyamide derivative | KOWA COMPANY, LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | JAK3, JAK1, UACA | JAK3 1/4885IRAK4 128/4885JAK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.